Jiuzhou Pharmaceutical(SH:603456) Zheng Quan Zhi Xing·2025-08-05 16:10Core Viewpoint - The company plans to increase capital for its subsidiary, Jiuzhou Pharmaceutical (Taizhou) Co., Ltd., using part of the raised funds from its non-public stock issuance, which has been approved by the board and supervisory committee without needing shareholder approval [1][7]. Group 1: Fundraising Overview - The company raised a total of approximately RMB 2.5 billion through a non-public issuance of 65,291,198 shares at a price of RMB 38.29 per share [2]. - The funds have been verified and stored in a dedicated account as per regulatory requirements [3][6]. Group 2: Capital Increase Details - The capital increase amount is set at RMB 200 million, which will raise the registered capital of Jiuzhou Pharmaceutical (Taizhou) from RMB 175 million to RMB 190 million [5]. - The capital surplus of RMB 185 million will be included in the capital reserve, and Jiuzhou Pharmaceutical (Taizhou) will remain a wholly-owned subsidiary of the company [5]. Group 3: Financial Data of Jiuzhou Pharmaceutical (Taizhou) - As of June 30, 2025, the total assets of Jiuzhou Pharmaceutical (Taizhou) were approximately RMB 1.54 billion, with liabilities of about RMB 610 million and net assets of around RMB 933 million [5]. - The company reported a revenue of approximately RMB 98.26 million for the first half of 2025, with a net loss of about RMB 28.35 million [5]. Group 4: Purpose and Impact of Capital Increase - The capital increase aims to meet the actual construction needs of the fundraising project without altering the investment direction or project content [7]. - This move is expected to enhance the efficiency of fund utilization and ensure the smooth implementation of the investment projects, aligning with the company's long-term strategic goals [7]. Group 5: Opinions from Supervisory and Sponsoring Institutions - The supervisory committee supports the capital increase, stating it aligns with the interests of the company and all shareholders [7]. - The sponsoring institution, Huatai United Securities, confirms that the capital increase complies with relevant regulations and does not affect the normal implementation of the investment projects [8].